PharmARC is a 100% life sciences focused company that provides analytic solutions for efficient commercialization of drugs and medical products. We enable our customers to make informed decisions related to their sales and marketing strategies, and implementation, yielding better ROI.
Founded in 2004, PharmARC has grown to become the top ten emerging companies in India (NASSCOM Emerge 2009), optimising the efficiencies and effectiveness of the commercialization process for customers in the life sciences industry worldwide.
Market assessment, forecasting, competitive intelligence, epidemiology studies, and key opinion leader management
We work in all areas of sales and marketing analytics; our key focus includes market assessment, forecasting, competitive intelligence, epidemiology studies, and key opinion leader management.
Our customers include 15 of the top 20 pharmaceutical companies and over 50 life sciences companies across the US, Europe, parts of Middle East, and the Asia-Pacific region. To enable efficiencies in commercialisation, we offer short, medium, and long-term engagement models which comprise of comprehensive consultation to understand the key customer issues, and solutions that are enabled with the right data, analytics and technology.
We are certified for ISO 27001: 2005 and HIPAA compliance; this ensures that we uphold industry-defined standards for information security and data privacy across all our customer engagements.
PharmARC is funded by individual investors and India's leading PE firm, Baring Private Equity. We are headquartered in Bangalore, India, with offices in Basel and New Jersey.
Virtual Analyst - A unique offering from PharmARC
Virtual Analyst is centered on providing cross functional analytics support to sales managers and reps that help them tailor their offerings to meet individual customer needs and enhance their sales efforts.
Our team of consultants have prior experience as sales reps and understand the day-to-day challenges of sales reps in the field. Click here to find out more.